Whittier Trust Co. of Nevada Inc. maintained its stake in shares of C.R. Bard, Inc. (NYSE:BCR) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 482 shares of the medical instruments supplier’s stock at the end of the second quarter. Whittier Trust Co. of Nevada Inc.’s holdings in C.R. Bard were worth $152,000 as of its most recent filing with the SEC.
Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of C.R. Bard by 2.7% in the first quarter. Vanguard Group Inc. now owns 7,881,464 shares of the medical instruments supplier’s stock valued at $1,958,858,000 after buying an additional 205,186 shares during the last quarter. BlackRock Inc. increased its stake in shares of C.R. Bard by 1,365.7% in the first quarter. BlackRock Inc. now owns 7,398,081 shares of the medical instruments supplier’s stock valued at $1,838,719,000 after buying an additional 6,893,346 shares during the last quarter. State Street Corp increased its stake in shares of C.R. Bard by 3.5% in the first quarter. State Street Corp now owns 3,831,621 shares of the medical instruments supplier’s stock valued at $952,313,000 after buying an additional 128,045 shares during the last quarter. Fundsmith LLP increased its stake in shares of C.R. Bard by 2.1% in the first quarter. Fundsmith LLP now owns 2,553,141 shares of the medical instruments supplier’s stock valued at $633,996,000 after buying an additional 52,272 shares during the last quarter. Finally, FMR LLC boosted its stake in shares of C.R. Bard by 4.2% in the first quarter. FMR LLC now owns 986,276 shares of the medical instruments supplier’s stock valued at $245,129,000 after buying an additional 39,817 shares during the period. 85.32% of the stock is owned by institutional investors and hedge funds.
Shares of C.R. Bard, Inc. (NYSE BCR) opened at 318.63 on Thursday. C.R. Bard, Inc. has a 12-month low of $203.63 and a 12-month high of $323.27. The firm’s 50-day moving average is $318.77 and its 200-day moving average is $282.55. The company has a market capitalization of $23.16 billion, a price-to-earnings ratio of 41.83 and a beta of 0.59.
C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The company had revenue of $979.70 million for the quarter, compared to the consensus estimate of $976.53 million. During the same quarter last year, the company earned $2.54 earnings per share. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, equities analysts predict that C.R. Bard, Inc. will post $11.84 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were given a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date was Thursday, July 20th. C.R. Bard’s payout ratio is currently 13.67%.
BCR has been the subject of several analyst reports. Jefferies Group LLC lifted their price objective on shares of C.R. Bard from $237.00 to $317.00 and gave the stock a “hold” rating in a research note on Monday, April 24th. Cowen and Company lifted their price objective on shares of C.R. Bard from $240.00 to $317.00 and gave the stock a “market perform” rating in a research note on Monday, April 24th. Morgan Stanley cut shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 24th. BMO Capital Markets cut shares of C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 target price for the company. in a research report on Tuesday, April 25th. Finally, Raymond James Financial, Inc. restated a “market perform” rating and issued a $265.00 target price on shares of C.R. Bard in a research report on Tuesday, April 25th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $285.67.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
